Buscar
Cumberland Pharmaceuticals Inc
CPIXAñadir a la lista de seguimiento
6.680USD
-0.050-0.74%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
100.09MCap. mercado
PérdidaP/E TTM
Más Datos de Cumberland Pharmaceuticals Inc Compañía
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Información de Cumberland Pharmaceuticals Inc
Símbolo de cotizaciónCPIX
Nombre de la empresaCumberland Pharmaceuticals Inc
Fecha de salida a bolsaAug 11, 2009
Director ejecutivoKazimi (A. J)
Número de empleados91
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 11
Dirección1600 West End Avenue, Suite 1300
CiudadNASHVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal37203
Teléfono18774842700
Sitio Webhttps://www.cumberlandpharma.com/
Símbolo de cotizaciónCPIX
Fecha de salida a bolsaAug 11, 2009
Director ejecutivoKazimi (A. J)
Ejecutivos de Cumberland Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--
Mr. A. J. Kazimi
Mr. A. J. Kazimi
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Gordon R. Bernard, M.D.
Dr. Gordon R. Bernard, M.D.
Independent Director
Independent Director
--
--
Mr. James L. (Jim) Herman
Mr. James L. (Jim) Herman
Vice President - Trade and Distribution
Vice President - Trade and Distribution
--
--
Mr. Joseph C. Galante
Mr. Joseph C. Galante
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
4.68K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cumberland Pharmaceuticals Inc?
Los cinco principales accionistas de Cumberland Pharmaceuticals Inc son: Mr. Kenneth J. Krogulski
¿Cuántas instituciones poseen acciones de Cumberland Pharmaceuticals Inc (CPIX)?
A fecha de 2026Q1, 59 instituciones poseen acciones de Cumberland Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 2.95M, lo que representa el 19.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1007470.00.
¿Cuál es la mayor fuente de ganancias de Cumberland Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Sancuso generó la ganancia más alta para Cumberland Pharmaceuticals Inc, ascendiendo a 11.91M y representando el 26.74% de la ganancia total.